Home / Science / Australia Leads in Advanced RNA Manufacturing
Australia Leads in Advanced RNA Manufacturing
7 May
Summary
- RNA therapeutics offer novel ways to combat diseases at the genetic level.
- Syngenis Laboratories is Australia's sole custom synthetic DNA/RNA manufacturer.
- A new GMP facility by Syngenis will be operational in 2026.
Next-generation RNA therapies offer a revolutionary approach to medicine by acting as molecular dimmer switches for genetic instructions. These advanced treatments intervene at the RNA level, potentially influencing multiple disease pathways simultaneously and improving conditions like insulin sensitivity, an area largely untouched by current therapies.
The manufacturing of RNA therapeutics requires significant technical sophistication, involving precise chemical synthesis and modifications to ensure molecule survival within the body. This demands a higher level of quality control than standard pharmaceutical production, highlighting the importance of specialized facilities.
Syngenis Laboratories, based in Perth, stands as Australia's sole commercial producer of custom synthetic DNA and RNA oligonucleotides. The company is a key partner in the ProGenis collaboration, responsible for generating the precise RNA molecules essential for their therapeutic platform.
Managing Director Thomas Hanly emphasized the need for advanced molecular engineering in these therapies, stating Syngenis's commitment to ensuring biological effectiveness, reproducibility, and scalability for clinical use. The company is transitioning from research-grade to human-grade manufacturing with a new Good Manufacturing Practice (GMP) facility scheduled for operation in 2026, positioning it as a unique asset for companies like ProGenis in Australia.
